Biomarker Gene Detection for Contact Normalization Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments struggle to effectively detect and target cancer cells that have undergone Contact Normalization, a process where nontransformed cells inhibit the growth of neighboring transformed cells, leading to challenges in diagnosing and treating cancer, particularly in addressing metastatic potential.
Innovation Solution
Identification and utilization of specific biomarker genes and gene products that are modulated during Contact Normalization, allowing for the detection and targeting of cancer cells, including the use of antisense oligonucleotides, siRNA, and ribozymes to inhibit the expression of these biomarkers, thereby blocking malignant growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer detection and treatment methods are used, then general cancer treatment is achieved, but cancer cells that have undergone Contact Normalization cannot be effectively detected or targeted
Solution Approach 1:
The patent identifies and utilizes changes in gene expression parameters that occur during Contact Normalization. By detecting specific biomarker genes and gene products whose expression levels change when cancer cells undergo Contact Normalization, the method can reliably detect these previously undetectable cells, thus resolving the contradiction between reliable cancer detection and adaptability to Contact Normalized cells.
2Reliability
If broad-spectrum chemotherapeutic agents are used, then cancer cell growth is inhibited, but noncancerous cells are also affected
Solution Approach 1:
The patent employs antisense oligonucleotides, siRNA, and ribozymes that are specifically designed to target and inhibit the expression of biomarker genes and gene products uniquely or preferentially expressed in cancer cells. This localized genetic targeting approach allows selective inhibition of cancer cell growth while sparing noncancerous cells, thereby resolving the contradiction between treatment effectiveness and harm to healthy cells.
3Ease of operation
If traditional diagnostic methods are used, then general cancer diagnosis is achieved, but metastatic potential cannot be accurately determined
Solution Approach 1:
The patent develops a multi-functional diagnostic approach using biomarker gene expression analysis that simultaneously provides general cancer diagnosis and assessment of metastatic potential. The same biomarker panel and detection methods can identify the presence of cancer cells while also evaluating their metastatic characteristics, thus resolving the contradiction between diagnostic simplicity and precision in metastatic potential assessment.
Data Source
AI summary
Using gene expression analysis, specific biomarker genes and gene products have been identified which are activated in transformed cells, but suppressed in nontransformed cells; or suppressed in transformed cells, but activated in transformed cells affected by Contact Normalization. Thus, the present invention features compositions and methods for detecting, diagnosing, treating and prognosing cancer.